Thousand Oaks biotech giant Amgen, along with partners Novartis and Banner Alzheimer’s Institute, are discontinuing a clinical research program that was aimed at preventing or delaying the onset of Alzheimer’s disease in at-risk individuals. The company announced the news in a July 11 news release, which stated that “after a review of clinical data, sponsors…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
